EASD 2025
15 - 19 September 2025
Incidence of non-arteritic ischaemic optic neuropathy (NAION) across completed phase 2, 3 and 4 trials evaluating the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide
Keywords
Get notified when materials for EASD 2025 and future congresses become available:
Get notified when materials for EASD 2025 and future congresses become available:
Success
We will notify you when new materials become available for EASD 2025 and future congresses.
We will keep you updated in your inbox:
Almost Done